Optimising patient centred drug development to realise impact
Patient-reported outcomes can provide valuable evidence on the efficacy and tolerability of treatments throughout the drug development pipeline supporting regulatory decision-making, reimbursement and patient-centred care. Use of international guidelines and tools can optimise assessment and data quality and maximise impact. Calvert et al. highlight how patient-reported outcomes (PROs) provide critical evidence for drug regulation, reimbursement, and clinical care. They advocate for using international guidelines and tools to enhance data quality and maximize the impact of these data to support decision-making and patient-centred care.
Institutions
- Advocates for Youth (US)
- Institute of Cancer Research (GB)
- Johns Hopkins University (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- NIHR Birmingham Biomedical Research Centre (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-05-19
- DOI
- https://doi.org/10.1038/s43856-026-01634-2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Gilead Sciences
- Sarcoma UK
- Merck KGaA
- Macmillan Cancer Support
- LifeArc
- University Hospitals Birmingham NHS Foundation Trust
- UK Research and Innovation
- Anthony Nolan
- National Institute for Health and Care Research
- Surgical Reconstruction and Microbiology Research Centre
- European Regional Development Fund
- Birmingham Biomedical Research Centre
- National Institute for Health Research Applied Research Collaboration West
- UCB Pharma